{"id":307764,"date":"2026-10-14T13:07:13","date_gmt":"2026-10-14T07:37:13","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=307764"},"modified":"2026-10-14T13:07:13","modified_gmt":"2026-10-14T07:37:13","slug":"biologics-maker-specialty-ingredient-and-pharmacy-retail-stocks-roadmap-watch-guide","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/biologics-maker-specialty-ingredient-and-pharmacy-retail-stocks-roadmap-watch-guide\/","title":{"rendered":"3 Biologics Maker, Specialty Ingredient and Pharmacy Retail Stocks With a Strong Future Roadmap: Shilpa Medicare, Viyash Scientific and Medplus Health Services"},"content":{"rendered":"

Shilpa Medicare Rs 973.60, P\/E 67.52. Viyash Scientific Rs 235.02, P\/E 39.01. Medplus Rs 617.00, P\/E 36.06. Closing prices of 13 Oct 2026.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Biologics maker, specialty ingredient and pharmacy retail stocks with the clearest long-term roadmaps today include Shilpa Medicare in active ingredients, formulations, biologics and contract manufacturing, Viyash Scientific in active pharmaceutical ingredients, formulations and contract manufacturing and Medplus in a pharmacy retail chain with a growing private label range, mainly in southern India. FY26 revenue growth was 18.2% at Shilpa Medicare, 14.0% at Viyash Scientific and 12.6% at Medplus. P\/E stands at 67.52 for Shilpa Medicare (industry 37.59), 39.01 for Viyash Scientific (industry 37.59) and 36.06 for Medplus (industry 66.59). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.<\/p>\n<\/p><\/div>\n

Biologics maker, specialty ingredient and pharmacy retail stocks give investors exposure to medicines and pharmacy services that doctors, drug makers and patients rely on. Contract orders, ingredient volumes and store growth decide how much of that demand turns into profit.<\/p>\n

This list covers three biologics maker, specialty ingredient and pharmacy retail stocks: Shilpa Medicare for active ingredients, formulations, biologics and contract manufacturing, Viyash Scientific for active pharmaceutical ingredients, formulations and contract manufacturing and Medplus Health Services for a pharmacy retail chain with a growing private label range, mainly in southern India. Every figure comes from the latest reported financials and the 13 October 2026 market close. Companies without complete current figures were left out.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n